Company sees full-year COVID sales of $6 billion to $8 billion but says size of U.S. market is still uncertain
With its shares under pressure due to revised COVID guidance from Pfizer Inc. PFE, +3.91%, Moderna Inc. MRNA, -3.80% on Monday said it “remains comfortable” with its existing guidance on full-year 2023 COVID-19 sales.
Moderna reiterated that full-year COVID vaccines sales are expected to be in the range of $6 billion to $8 billion, guidance previously provided in its August earnings release. The company also sounded a note of caution, saying in a statement Monday that “it is still too early in the U.S. vaccination season to accurately project where vaccination rates will land for the full year.”
Moderna expects to have a better picture of the expected U.S. market size at the end of October, the company said, and will provide an update when it reports quarterly results Nov. 2. Pfizer’s announcement Friday that it was slashing its full-year outlook due to lower expected COVID-19 sales weighed on shares of vaccine makers Monday. Moderna shares fell 4% Monday morning, while Novavax NVAX, -4.68% stock fell 0.4%, and BioNTech’s American depositary receipts BNTX, -6.26% fell 6.7%, while Pfizer shares gained 3% after a steep drop Friday.
Malaysia Latest News, Malaysia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Stock movers: Pfizer, Lululemon, BioNTech, Moderna, Novavax, Manchester UnitedLululemon stock climbs ahead of S&P 500 inclusion
Read more »
Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting DemandI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Read more »
Vaccine Stocks—Including Pfizer, Moderna, BioNTech And Novavax—Slide Amid Plummeting DemandI am a senior reporter for the Forbes breaking news team, covering health and science from the London office. Previously I worked as a reporter for a trade publication covering big data and law and as a freelance journalist and policy analyst covering science, tech and health.
Read more »
Pfizer slumps after slashing full-year profit forecast on tumbling Covid salesPfizer said slumping demand for its Comirnaty covid vaccine and its Paxlovid antiviral treatment will mean sharply lower revenues for the full year.
Read more »
Pfizer, BioNTech shares fall on lower COVID product sales forecastShares of Pfizer (PFE.N) and German partner BioNTech (22UAy.DE) fell on Monday after the U.S. drugmaker slashed the sales forecast for its COVID vaccine and therapy last week, and some analysts said the reduction was bigger than expectations.
Read more »
Pfizer cuts full-year outlook due to declining sales of Covid-19-related productsShares of Pfizer are falling before the opening bell as the company cut its full-year outlook, citing declining sales of its COVID-19-related products. Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion. Its prior forecast was for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.
Read more »